A nurse is teaching a client who has a new prescription for nitroglycerin sublingual tablets for treating angina. Which of the following instructions should the nurse include in the teaching?

A) "Call 911 if pain persists 30 minutes after taking one tablet": This instruction is not accurate and could potentially delay appropriate medical intervention for angina. Nitroglycerin sublingual tablets are rapid-acting vasodilators used to relieve acute angina symptoms. If chest pain persists after taking one tablet, the client should take another tablet after 5 minutes. If the pain persists after a total of three tablets, the client should seek emergency medical assistance.

B) "Place the tablet under the tongue until dissolved": This instruction is correct. Nitroglycerin sublingual tablets should be placed under the tongue and allowed to dissolve completely. Sublingual administration allows for rapid absorption of the medication into the bloodstream, providing quick relief of angina symptoms.

C) "Store the tablets in a refrigerator in a plastic container": This instruction is incorrect. Nitroglycerin sublingual tablets should be stored in their original container at room temperature, away from moisture and heat. Storing them in the refrigerator could alter their effectiveness.

D) "Take a tablet every 10 minutes until the pain subsides": This instruction is incorrect and potentially dangerous. Nitroglycerin sublingual tablets should be taken as directed by the healthcare provider or based on the client's angina management plan. Typically, the client should take one tablet at the onset of angina symptoms and repeat the dose every 5 minutes if the pain persists, up to a maximum of three tablets within 15 minutes. Taking a tablet every 10 minutes without regard to symptom relief or maximum dosage limits could lead to hypotension and other adverse effects.

A) Digoxin and levothyroxine: Digoxin is a cardiac glycoside used to treat heart failure and atrial fibrillation, while levothyroxine is a thyroid hormone replacement medication used to treat hypothyroidism. While both medications have potential side effects, hearing loss is not typically associated with either digoxin or levothyroxine. Therefore, monitoring for hearing loss related to a medication interaction is not a priority for clients taking digoxin and levothyroxine.

B) Losartan and atorvastatin: Losartan is an angiotensin II receptor blocker used to treat hypertension, while atorvastatin is a statin medication used to lower cholesterol levels. Hearing loss is not a known side effect of either losartan or atorvastatin, nor is there evidence of an interaction between these medications that would increase the risk of hearing loss. Therefore, monitoring for hearing loss related to a medication interaction is not indicated for clients taking losartan and atorvastatin.

C) Propranolol and raloxifene: Propranolol is a beta-blocker used to treat hypertension, angina, and other cardiovascular conditions, while raloxifene is a selective estrogen receptor modulator used to prevent and treat osteoporosis in postmenopausal women. Neither propranolol nor raloxifene is associated with hearing loss as a common side effect. Additionally, there is no known interaction between propranolol and raloxifene that would increase the risk of hearing loss. Therefore, monitoring for hearing loss related to a medication interaction is not necessary for clients taking propranolol and raloxifene.

D) Furosemide and amikacin: Furosemide is a loop diuretic that is commonly used to treat fluid overload conditions such as heart failure and edema. Amikacin is an aminoglycoside antibiotic used to treat bacterial infections. Both furosemide and amikacin have the potential to cause ototoxicity, which can manifest as hearing loss or tinnitus. When administered concurrently, especially at higher doses or for prolonged durations, the risk of ototoxicity may increase due to additive or synergistic effects on the inner ear structures. Therefore, the nurse should monitor clients receiving both furosemide and amikacin for signs of hearing loss, such as changes in hearing acuity or tinnitus, and promptly report any concerns to the healthcare provider for further evaluation and management.